IL166022A0 - Use of HMGB1 in the treatment of tissue damage and/or to promote tissue repair - Google Patents

Use of HMGB1 in the treatment of tissue damage and/or to promote tissue repair

Info

Publication number
IL166022A0
IL166022A0 IL16602204A IL16602204A IL166022A0 IL 166022 A0 IL166022 A0 IL 166022A0 IL 16602204 A IL16602204 A IL 16602204A IL 16602204 A IL16602204 A IL 16602204A IL 166022 A0 IL166022 A0 IL 166022A0
Authority
IL
Israel
Prior art keywords
treatment
tissue
hmgb1
promote
hmgbl
Prior art date
Application number
IL16602204A
Other languages
English (en)
Original Assignee
Idi Irccs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idi Irccs filed Critical Idi Irccs
Publication of IL166022A0 publication Critical patent/IL166022A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
IL16602204A 2002-07-03 2004-12-28 Use of HMGB1 in the treatment of tissue damage and/or to promote tissue repair IL166022A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39399402P 2002-07-03 2002-07-03
PCT/IT2003/000265 WO2004004763A2 (en) 2002-07-03 2003-04-29 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair

Publications (1)

Publication Number Publication Date
IL166022A0 true IL166022A0 (en) 2006-01-15

Family

ID=30115667

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16602204A IL166022A0 (en) 2002-07-03 2004-12-28 Use of HMGB1 in the treatment of tissue damage and/or to promote tissue repair

Country Status (14)

Country Link
US (1) US20060035851A1 (de)
EP (1) EP1519957B1 (de)
JP (1) JP2005537253A (de)
KR (1) KR20050054907A (de)
CN (1) CN1671742A (de)
AT (1) ATE424416T1 (de)
AU (1) AU2003228099A1 (de)
CA (1) CA2491321A1 (de)
DE (1) DE60326453D1 (de)
IL (1) IL166022A0 (de)
MX (1) MXPA05000302A (de)
NO (1) NO20050537L (de)
RU (1) RU2005102593A (de)
WO (1) WO2004004763A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
EP1768693A1 (de) * 2004-07-20 2007-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'Immacolata Concezione - Istituto Dermopatico Dell'Immacolata Verwendung von hmgb1 zur wundheilung
US7585504B2 (en) 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
US7795314B2 (en) 2005-06-01 2010-09-14 Cytokine Pharmasciences, Inc. Protective role of semapimod in necrotizing enterocolitis
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
WO2007130725A2 (en) * 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
JP3882090B1 (ja) 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
WO2008053892A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceutical for promoting functional regeneration of damaged tissue
AU2014200688C1 (en) * 2006-10-30 2016-04-21 Genomix Co., Ltd. Pharmaceuticals that promote functional regeneration of damaged tissues
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
ES2654542T3 (es) 2008-04-30 2018-02-14 Genomix Co., Ltd. Procedimiento de recolección de células funcionales in vivo con alta eficiencia
EP2301560A4 (de) * 2008-04-30 2012-05-09 Genomix Co Ltd Pharmazeutisches mittel zur föderung der funktionalen regeneration von geschädigtem gewebe
JP5660889B2 (ja) * 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
US11191786B2 (en) 2009-10-28 2021-12-07 StemRIM Inc. Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
ES2486321T3 (es) * 2010-06-18 2014-08-18 Xiberscience Gmbh Péptidos como agentes activos para estabilizar barreras biológicas
CN102375064A (zh) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒
EP4066826B1 (de) * 2010-09-01 2024-03-06 Thomas Jefferson University Retinsäure-rezeptor-gamma-agonisten zur muskelreparatur und -regeneration
EP2703487B1 (de) * 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide zur induktion der regenerierung von gewebe und verwendung davon
WO2014016417A1 (en) * 2012-07-26 2014-01-30 Ospedale San Raffaele Srl Hmgb1 variants and uses thereof
AU2013335684B2 (en) * 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
DK2913059T3 (en) 2012-10-25 2018-06-25 Genomix Co Ltd Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
CN103316378B (zh) * 2013-06-27 2014-07-16 重庆大学 一种hmgb 1修饰的骨组织工程支架材料及其制备方法
KR102365492B1 (ko) 2015-04-22 2022-02-18 삼성전자주식회사 웨어러블 기기
AU2016366515A1 (en) 2015-12-11 2018-06-21 Ruprecht-Karls-Universität Heidelberg Combined preparations of PKM2 modulators and HMGB1
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
CN106244589A (zh) * 2016-08-01 2016-12-21 中国人民解放军第四军医大学 靶向hmgb1基因的rna干扰片段及其应用
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
AU2018257071B2 (en) 2017-04-25 2021-11-11 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
CA3084013A1 (en) 2017-12-01 2019-06-06 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
JP7805925B2 (ja) * 2019-11-12 2026-01-26 オックスフォード ユニバーシティ イノベーション リミテッド 組織再生の促進に有用なｈｍｇｂ１に関連するポリペプチド、それを含む組成物、及びその使用
CN111381050B (zh) * 2020-04-21 2023-06-20 南通大学 Reg3β/ HMGB1环路调控EAM小鼠巨噬细胞再编程的实验方法
WO2022243932A1 (en) * 2021-05-19 2022-11-24 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
WO2023037562A1 (ja) * 2021-09-07 2023-03-16 国立大学法人大阪大学 肺炎の治療薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548122A1 (de) * 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
WO2002074301A1 (en) * 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
US7754217B2 (en) 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EP1392844A4 (de) * 2001-05-15 2006-09-06 Long Island Jewish Res Inst Verwendung von hmg-fragmenten als entzündungshemmende mittel

Also Published As

Publication number Publication date
EP1519957A2 (de) 2005-04-06
WO2004004763A2 (en) 2004-01-15
US20060035851A1 (en) 2006-02-16
MXPA05000302A (es) 2005-08-19
WO2004004763A3 (en) 2004-02-26
ATE424416T1 (de) 2009-03-15
KR20050054907A (ko) 2005-06-10
RU2005102593A (ru) 2005-10-10
EP1519957B1 (de) 2009-03-04
CA2491321A1 (en) 2004-01-15
CN1671742A (zh) 2005-09-21
DE60326453D1 (de) 2009-04-16
AU2003228099A1 (en) 2004-01-23
JP2005537253A (ja) 2005-12-08
NO20050537L (no) 2005-02-01

Similar Documents

Publication Publication Date Title
IL166022A0 (en) Use of HMGB1 in the treatment of tissue damage and/or to promote tissue repair
WO2004089396A3 (en) Anti-fungal peptidomimetics
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
WO2006116731A3 (en) Personal care compositions comprising a dipeptide
PT2422789T (pt) Composição injetável compreendendo desoxicolato de sódio
MX2010003019A (es) Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
BR0316305A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit
TW200505508A (en) Methods of administering a dermatological agent to a subject
MX338122B (es) Epitopes terapeuticos y usos de los mismos.
TR200100149T2 (tr) Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
AR046933A1 (es) Eficacia de humectacion mejorada mediante el uso de hidroxialquilurea
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
BR0306665A (pt) Uso de zeìna nativa para aperfeiçoamento do estado do cabelo e agentes
WO2006099261A3 (en) Potent and specific immunoproteasome inhibitors
EA201100072A1 (ru) Новые композиции и способы
NO953093D0 (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2004039832A3 (en) Leptin-related peptides
WO2006057003A3 (en) Induction of neurogenesis and stem cell therapy in combination with copolymer 1
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
EA200100951A1 (ru) Комбинированная терапия ингибитором ангиотензинпревращающего фермента и эпоксистероидным антагонистом альдостерона для лечения сердечно-сосудистого заболевания